Matches in Wikidata for { <http://www.wikidata.org/entity/Q61907627> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- Q61907627 description "assaig clínic" @default.
- Q61907627 description "clinical trial" @default.
- Q61907627 description "clinical trial" @default.
- Q61907627 description "clinical trial" @default.
- Q61907627 description "clinical trial" @default.
- Q61907627 description "ensaio clínico" @default.
- Q61907627 description "ensayo clínico" @default.
- Q61907627 description "ensayu clínicu" @default.
- Q61907627 description "essai clinique" @default.
- Q61907627 description "klinisch onderzoek" @default.
- Q61907627 description "клінічне випробування" @default.
- Q61907627 description "临床试验" @default.
- Q61907627 name "Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer" @default.
- Q61907627 type Item @default.
- Q61907627 label "Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer" @default.
- Q61907627 prefLabel "Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer" @default.
- Q61907627 P1132 Q61907627-ED5F212C-E123-4863-8C95-4BE2E6942801 @default.
- Q61907627 P1476 Q61907627-B5C6B1F5-B853-4387-B5DB-183F6908FBE9 @default.
- Q61907627 P17 Q61907627-AAABC4F1-D815-494C-B9AB-A61B5D1CC227 @default.
- Q61907627 P2899 Q61907627-0BDF5521-ACE9-4810-A53E-1FB8F3EE0CEC @default.
- Q61907627 P3098 Q61907627-F5E805C8-90A7-4E4D-BA27-997AB0CC9009 @default.
- Q61907627 P31 Q61907627-3D9DF809-44B7-489E-BF16-418BD06737DE @default.
- Q61907627 P4844 Q61907627-8D1CDE97-7B10-4B2A-9344-54E66BD23A9E @default.
- Q61907627 P4844 Q61907627-A0D58F9C-418B-4E7A-958F-C3CC4DDADC63 @default.
- Q61907627 P580 Q61907627-0EEF983C-D885-4CDF-AA29-0465ACC369EB @default.
- Q61907627 P582 Q61907627-50EB3261-FFC1-4FC5-A2E0-7A44B6EB6B25 @default.
- Q61907627 P6099 Q61907627-ED9AC229-D086-4A23-A751-DD31A031E04C @default.
- Q61907627 P6153 Q61907627-AE915B04-F523-47B5-83D8-A19B42D13B35 @default.
- Q61907627 P8005 Q61907627-D2DBC8B8-14B2-4912-8430-16C01DFFBC09 @default.
- Q61907627 P8363 Q61907627-A072C667-A9E9-43B5-B0F7-CB67A338A296 @default.
- Q61907627 P859 Q61907627-E4DABC35-D063-4CEE-9EFB-6DE2EF6C626A @default.
- Q61907627 P1132 "+74" @default.
- Q61907627 P1476 "Phase II Study of Radiation Therapy and Anti-PD-L1 Checkpoint Inhibitor (Durvalumab) With or Without Anti-CTLA-4 Inhibition (Tremelimumab) in Patients With Unresectable, Locally Advanced, or Metastatic Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy" @default.
- Q61907627 P17 Q30 @default.
- Q61907627 P2899 "+18" @default.
- Q61907627 P3098 "NCT03601455" @default.
- Q61907627 P31 Q30612 @default.
- Q61907627 P4844 Q20801760 @default.
- Q61907627 P4844 Q7838098 @default.
- Q61907627 P580 "2018-11-01T00:00:00Z" @default.
- Q61907627 P582 "2021-11-01T00:00:00Z" @default.
- Q61907627 P6099 Q42824440 @default.
- Q61907627 P6153 Q174710 @default.
- Q61907627 P8005 Q76649708 @default.
- Q61907627 P8363 Q78089383 @default.
- Q61907627 P859 Q6275910 @default.